• “Cancer therapeutic targeting using mutant-p53-specific siRNAs”. Ubby I, Krueger C, Rosato R, Qian W, Chang J, Sabapathy K. Oncogene. 2019. 38:3415-3427.
• “Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others”. Sabapathy K and Lane DP. Nature Review Clinical Oncology. 2018. 15:13-30.
• “Novel tools for precision medicine - monoclonal antibodies against specific p53 hot-spot mutants”. Hwang LA, Phang BH, Liew OW, Iqbal J, Koh XH, Koh XY, Othman R, Xue Y, Richards AM, Lane DP* and Sabapathy K*. Cell Reports. 2018. 22:299-312. *: co-corresponding author
• Hypoxia-inducible TAp73 regulates the angiogenic transcriptome and supports tumorigenesis”.
Dulloo I, Phang BH, Othman R, Tan SY, Vijayaraghavan A, Goh LK, Martin-Lopez M, Marques MM, Li CW, Wang DY, Marin MC, Xian W, McKeon F and Sabapathy K. Nature Cell Biol. 2015. 17:511-523.
• “Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis”. Phang BH, Othman R, Bougeard G, Chia RH, Frebourg T, Tang CL, Cheah PY, Sabapathy K. Proc Natl Acad Sci U S A. 2015. 112:6349-6358.